Immuno-oncology and immunotherapy Part C (Volume 191) (Methods in Cell Biology, Volume 191). Questo articolo non è disponibile.Immuno-oncology and immunotherapy Part C (Volume 191) (Methods in Cell Biology, Volume 191)

Immuno-oncology and immunotherapy, Part C, Volume 191 in the Methods in Cell Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Extraction and quantification of histones from human cells, Expression and characterization of Phosphatidylserine-targeting antibodies for biochemical and therapeutic applications, ILC differentiation from HSCs in vitro, Methods to expand human Treg cells and assay their function, Monitoring rapid activation of human gamma/delta T cells by multicolor flow cytometry, Methods to induce T cell exhaustion in vitro, Ex vivo assessment of human neutrophil motility and migration, and much more.

Additional chapters focus on Flow cytometry-based monitoring of myeloid-derived suppressor cells in the peripheral blood of patients with solid tumors, Deciphering human blood and tumor neutrophil heterogeneity: Methods for isolation and assessing suppression of T-cell proliferation, Splenocyte anticancer citotoxicity assessment after prophylactic vaccination or drug treatment of tumor-bearing mice, Therapeutic treatment of tumor-bearing mice with drug-killed cancer cells: a method to confirm immunogenic cell death and assess its therapeutic effectiveness, and much more.

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.

Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Norma received her master’s degree in health biology from Paris Saclay. In 2013, she joined the laboratory of Dr. Guido Kroemer at the Centre de Recherche des Cordeliers (Paris, France) and at Gustave Roussy (Villejuif, France), the largest center for oncological patients in Europe. She worked on several projects linked to immunosurveillance, culminating with her obtaining her PhD in 2017 with an original work on “Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance”. She then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Galluzzi. Her current research is focused on investigating resistance to immunotherapy in a mouse model of HR+ breast cancer.

Maud Charpentier received her M.Sc. in Cellular Biology and her Ph.D. in Immunology from the University of Nantes, France. She chose to pursue an academic career and continued her postdoctoral training in the United States. She joined the Department of Radiation Oncology at Weill Cornell Medicine under the mentorship of Dr. Sandra Demaria. Maud has a long-standing interest in the anti-tumor immune response and its role in controlling cancer progression and treatment outcomes. Her research focuses on understanding the synergy between radiation therapy and immunotherapy in solid tumors, with the aim of overcoming resistance to treatment and developing innovative therapeutic approaches in preclinical models.